9 Meters
NMTR

From December 31, 2022 to March 31, 2023 Issuance of common stock and warrants

Common stock offered 1,300,000 shares by the company

From December 31, 2021 to December 31, 2022 Issuance of common stock Settlement of convertible debt and accrued interest

9 Meters Biopharma Announces 1-for-20 Reverse Stock Split.

From March 31, 2022 to June 30, 2022 Issuance of common stock

From December 31, 2020 to December 31, 2021 Issuance of common stock Exercise of warrants Exercise of stock options Vesting of RSUs

From June 30, 2021 to September 30, 2021 Issuance of common stock Exercise of warrants Exercise of stock options

From March 31, 2021 to June 30, 2021 Issuance of common stock Exercise of warrants Exercise of stock options

1.Common stock offered by the company 30,000,000 shares. 2.The number of shares of common stock outstanding is based on an aggregate of 204,629,064 shares outstanding as of December 31, 2020.

From December 31, 2020 To March 31, 2021 Exercise of warrants Exercise of stock options

from December 31, 2019 to December 31, 2020 Issuance of common stock Issuance of common stock (RDD & Naia mergers) Issuance of preferred stock and warrants (FN-1) Conversion of preferred stock to common stock Warrant exchange Issuance of RSUs Exercise of warrants Conversion of convertible debt and accrued interest

1.Common stock offered by the company 46,153,847 shares of common stock. 2.The number of shares of common stock outstanding is based on an aggregate of 149,575,457 shares outstanding as of September 30, 2020.

From June 30, 2020 to September 30, 2020 Issuance of common stock Exercise of warrants Conversion of convertible debt and accrued interest

From March 31, 2020 to June 30, 2020 Conversion of preferred stock to common stock Issuance of common stock (RDD & Naia mergers) Exercise of warrants Conversion of convertible debt and accrued interest Issuance of RSUs

From December 31, 2019 to March 17, 2020 Warrant exchange

From December 31, 2018 to December 31, 2019 Issuance of common stock Exercise of stock options Settlement of RSUs Warrant exchange

From March 31, 2019 to June 30, 2019 Issuance of common stock and warrants Exercise of stock options Issuance of RSUs

From December 31, 2018 to March 31, 2019 Issuance of common stock and warrants Issuance of RSUs

From December 31, 2017 to December 31, 2018 Issuance of shares as a result of reverse recapitalization Issuance of common stock Conversion of convertible debt and accrued interest Exercise of stock options Exercise of warrants, net of issuance costs

from December 31, 2017 to September 30, 2018 Issuance of shares as a result of reverse recapitalization Issuance of common stock Conversion of convertible debt and accrued interest Exercise of warrants, net of commissions

From December 31, 2017 to June 30, 2018 Issuance of shares as a result of reverse recapitalization Issuance of common stock Conversion of convertible debt and accrued interest Exercise of warrants

From December 31, 2017 to March 31, 2018 Issuance of shares as a result of reverse recapitalization Issuance of common stock Conversion of convertible debt and accrued interest

from December 31, 2016 to February 1, 2018 Issuance of common stock, net of issuance costs Issuance of common stock pursuant to stock option plan Issuance of common stock pursuant to consulting arrangements Issuance of common stock in connection with warrants exercise net of issuance costs Conversion of related party debt into equity Issuance of common stock pursuant to debt payment agreement Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced the completion of its merger (the "Merger") with Monster Digital, Inc. on January 30, 2018. In connection with the completed Merger, Monster Digital, Inc. was renamed Innovate Biopharmaceuticals, Inc. The change of the Nasdaq ticker symbol for Innovate Biopharmaceuticals was delayed due to technical issues and Innovate Biopharmaceuticals shares will continue to trade under Monster Digital's ticker (NASDAQ:MSDI) on Wednesday, January 31, 2018, and, during such time, Nasdaq share numbers will not reflect the 1 for 10 reverse split that occurred on January 30, 2018. We anticipate that Innovate Biopharmaceuticals shares will commence trading on Nasdaq with the new ticker INNT and will reflect the 1 for 10 reverse split in trading on Thursday, February 1, 2018.

from December 31, 2016 to September 30, 2017 Issuance of common stock, net of issuance costs Issuance of common stock pursuant to stock option plan Issuance of common stock pursuant to consulting arrangements Warrant exercise Conversion of related party debt into equity

from December 31, 2016 to June 30, 2017 Issuance of common stock, net of issuance costs Issuance of common stock pursuant to stock option plan Issuance of common stock pursuant to consulting arrangements Warrant exercise Conversion of related party debt into equity

from December 31, 2016 to March 31, 2017 Issuance of common stock, net of issuance costs Issuance of common stock pursuant to stock option plan

From December 31, 2015 to December 31, 2016 Issuance of preferred stock Conversion of preferred to common stock Exchange of debt for equity Issuance of common stock and warrants in IPO, net of issuance costs Issuance of restricted shares of common stock Issuance of restricted shares of common stock, net of issuance costs

1. an additional 1,405,007 shares to be issued further to the Conversion 2. an additional 134,043 shares of common stock to be issued further to the Company Conversion Issuance

From December 31, 2015 to June 30, 2016 Issuance of Preferred Stock Issuance of Common Stock A one-for-11.138103 reverse stock split of our common stock effected on January 7, 2016. A one-for-1.2578616 reverse stock split of our common stock effected on June 6, 2016. A one-for-1.06 reverse stock split of our common stock effected on June 23, 2016.

From December 31, 2015 to June 24, 2016 Issuance of Preferred Stock Issuance of Common Stock A one-for-11.138103 reverse stock split of our common stock effected on January 7, 2016. A one-for-1.2578616 reverse stock split of our common stock effected on June 6, 2016. A one-for-1.06 reverse stock split of our common stock effected on June 23, 2016.

On January 7, 2016, the Board of Directors of the Company approved a one-for-11.138103 reverse stock split.